Vismodegib

• vismodegib (VIS-moh-DEH-gib) is a drug used to treat advanced basal cell carcinoma that has spread to other parts of the body or has come back after surgery.

• It is also used in patients who cannot be treated with surgery or radiation therapy.

• It is also being studied in the treatment of other types of cancer.

• Vismodegib blocks a type of protein involved in tissue growth and repair and may block the growth of cancer cells.

• It is a type of Hedgehog signaling pathway antagonist. Also called Erivedge and GDC-0449.

Information about Vismodegib

Vismodegib is a kinase inhibitor active used in the therapy of unresectable or metastatic basal cell carcinoma.

Indications

Erivedge™ (vismodegib) capsule is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. (1) dosage and administration the recommended dose is 150 mg orally once daily. (2) dosage forms and strengths 150 mg capsules. (3) contraindications none.

Warnings and precautions

Embryo-fetal death and severe birth defects: erivedge can cause embryo-fetal death or severe birth defects. Blood donation: advise patients not to donate blood or blood products while receiving erivedge and for at least 7 months after the last dose of erivedge.

Vismodegib

Liver safety of Vismodegib

Vismodegib therapy is associated with a low rate or transient elevations in serum aminotransferase during therapy and has been linked to rare cases of clinically apparent acute liver injury. 

Mechanism of action of Vismodegib

Vismodegib (vis” moe deg’ ib) is an orally available, kinase inhibitor with specific activity against a key step (activation of smoothened: SMO) in the hedgehog signaling pathway. 

Hedgehog is a key regulator of embryonic development, cell growth and differentiation. 

Mutations in this pathway have been identified in several malignant diseases including basal cell carcinoma. 

Clinical trials of vismodegib in patients with metastatic or locally advanced basal cell carcinoma reported at least partial responses in up to half of patients. 

FDA approval information for Vismodegib

Vismodegib, the first hedgehog pathway inhibitor, was approved for use in the United States in 2012.  Current indications include metastatic or locally advanced, recurrent or unresectable basal cell carcinoma. 

Dosage and administration for Vismodegib

Vismodegib is available in capsules of 150 mg under the brand name Erivedge.  The typical dose is 150 mg once daily until disease progression or unacceptable toxicity occurs. 

Side effects of Vismodegib

Side effects are common and often dose limiting, although rarely life threatening. 

Common side effects include muscle spasms, alopecia, anorexia, dysguesia, weight loss, nausea, diarrhea, fatigue and arthralgias. 

Potential serious adverse events include severe weight loss, squamous cell skin cancer and embryo-fetal toxicity.

Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ

Cost and Coupons - Vismodegib

• GoodRx compare cost & coupons for Vismodegib
• Find the lowest cost of Vismodegib
• Search for Coupons for Vismodegib

Reviews for Vismodegib

• Reviews for Vismodegib

Learn more about Vismodegib

• Dailymed label info
• Scientific articles

Latest research (Pubmed)

• Most recent articles
• Most cited
• Ongoing trials

External links

• Wikipedia's article on Vismodegib

edit 

WikiMD needs you!

This WikiMD article Vismodegib is a stub.
If you are a healthcare professional familiar with the topic Vismodegib, or
A subject matter expert or authority on Vismodegib, you can help us.
About | Mission | Paid editors welcome!